Immune Repertoire Profiling Articles & Analysis: Older
4 articles found
Summary The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began in 2019 and rapidly scaled to a global presence of disease known as COVID-19. Despite the relatively fast implementation of testing and vaccination worldwide, the rise of emerging viral variants and breakthrough infections raises concerns that SARS-CoV-2 will continue to pose a global health threat. ...
In recent years, the increase in the number of multi-drug resistant pathogens and food safety have become serious global problems, and it is increasingly important to find or develop a new generation of antibacterial drugs or preservatives. Scientists have discovered that bacteria-produced bacteriocins can control clinically relevant susceptible and resistant bacteria, and purified bacteriocins ...
What are AAVs? and what makes them good candidates for gene therapy? Introduction In the first part of our three part series introducing AAV as a gene therapy vector, we talked about basic AAV vector biology. In this post, we’re going to take a step back to answer the question of “Why AAV?” and look at some opportunities in the AAV engineering space. Why AAV? Viral vectors ...
The challenges of evading both pre-existing immunity and de novo adaptive immune responses against AAV vectors are made especially difficult by the heterogeneous nature of patient immune responses and immune histories. ...